Legacy Pharmaceutical Packaging Recalls Lorazepam Tablets Due to Labeling Errors
Legacy Pharmaceutical Packaging LLC is recalling 1,644 bottles of Lorazepam 0.5 mg tablets because of incorrect or missing lot and expiration dates.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which by definition is unlikely to cause adverse health consequences, and the issue is limited to labeling errors.
Plain-English summary
Legacy Pharmaceutical Packaging LLC is recalling 1,644 bottles of Lorazepam 0.5 mg tablets, 100 count, prescription only. The product is distributed by Major Pharmaceuticals, Livonia, MI, under NDC 0904-6007-60. The specific lot number is L-04009 with an expiration date of 11/15.
The recall was initiated due to labeling issues where the lot and/or expiration date was incorrect or missing. This is classified as an FDA Class III recall, indicating that the use of or exposure to the product is not likely to cause adverse health consequences.
Distribution was made to Indiana. Consumers and healthcare providers should check their inventory for this specific lot and expiration date. If found, the product should be returned to the pharmacy or distributor for credit.
The recalled product
- Product
- LORAZEPAM (LORAZEPAM)
- Brand
- LORAZEPAM
- Manufacturer
- Legacy Pharmaceutical Packaging LLC
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 1,644
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- L-04009 Exp.11/15
Distribution
Distributed in 1 state:
Related recalls
Same brand · LORAZEPAM
- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- HighLorazepam Tablets Recalled Due to Sub-Potency and Failed Stability Testing
FDA (Drugs) · 2025-02-26
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam injection vials recalled for elevated impurities and degradation
FDA (Drugs) · 2023-05-24
Same manufacturer · Legacy Pharmaceutical Packaging LLC
See all →- HighSertraline Hydrochloride Tablets Recalled Due to Manufacturing Process Defect
FDA (Drugs) · 2024-01-03
- ModerateLegacy Pharmaceutical Recalls Metformin Tablets Due to Foreign Imprint
FDA (Drugs) · 2020-10-07
- SevereLosartan Potassium Tablets Recalled Due to Trace Nitrosamine Impurity
FDA (Drugs) · 2019-05-08
- SevereLosartan Potassium Tablets Recalled Due to Impurity Detection
FDA (Drugs) · 2019-04-10
- SevereLosartan Potassium Tablets Recalled Due to Impurity Presence
FDA (Drugs) · 2019-03-27
Same hazard · mis labeling
See all →- ModerateMedline Trach Tube Kit Recalled for Component Labeling Discrepancy
FDA (Devices) · 2026-09-02
- ModerateAVID Medical Recalls Halyard Total Joint Kits for Latex Labeling Deficiency
FDA (Devices) · 2026-09-02
- ModerateOlympus Recalls PowerSeal Sealer Due to Incorrect Outer Box Labeling
FDA (Devices) · 2026-09-02
- HighSura Tanmen Ramen Noodles Recalled for Undeclared Fish Allergens
FDA (Food) · 2026-09-02
- SevereWhite Vein Advanced Alkaloids Chewable Tablets Recall for Excess Active Ingredient
FDA (Food) · 2026-09-02